Strategic Expansion to Boost Production
Amneal Pharmaceuticals, a prominent US-based pharmaceutical company, has announced plans to significantly expand its manufacturing capabilities in India. The company intends to invest up to USD 200 million over the next four to five years. This investment will fund the construction of two new manufacturing facilities in Ahmedabad, enhancing Amneal’s capacity to produce advanced pharmaceutical products.
The planned facilities will specialize in peptide synthesis and advanced sterile fill-finish manufacturing. These greenfield projects are set to elevate Amneal’s position as a leader in the production of branded medicines, not only for the Indian market but for global distribution as well.
Commitment to Innovation and Growth
Amneal Pharmaceuticals has established a strong presence in India since beginning operations in 2008, with eight manufacturing sites across the country, including five in Ahmedabad. The addition of the two new facilities is expected to further strengthen the company’s commitment to developing and manufacturing innovative medicines on a large scale.
Co-founders and Co-Chief Executive Officers, Chirag Patel and Chintu Patel, expressed pride in leading the way for pharmaceutical innovation and manufacturing in India. “With these new facilities, we are proud to be at the forefront of developing and manufacturing innovative, branded medicines at scale in India, which will supply the local market and the rest of the world,” they stated.
A Decade of Significant Investments
Over the past decade, Amneal has invested approximately USD 600 million in India, demonstrating a robust commitment to its growth strategy in the region. The existing facilities in India collectively produce up to 60 million units of injectables and 8.5 billion tablets annually. The new investment is expected to not only create high-quality products but also generate substantial employment opportunities in the region.
This strategic expansion underscores Amneal Pharmaceuticals’ ongoing commitment to enhancing global healthcare through innovative and efficient manufacturing processes.
